BASF and Catalent join forces to address NME bioavailability challenges

Privately-held USA-based Catalent Pharma Solutions has joined forces with German drug giant BASF (BAS: DE) in a broad collaboration to provide solutions to overcome bioavailability challenges of new molecular entities (NMEs) with solubility or permeability challenges.

The companies aim to combine their world-leading expertise to provide pharmaceutical customers with a unique range of seamless solutions to address pipeline challenges with a large majority of BCS Class II and IV poorly bioavailable compounds. From feasibility studies across multiple technologies, solid state chemistry, consulting and training, expert formulation services, excipients and optimal dose form development, to scale-up and supply, BASF and Catalent provide a full solution to one of the most important pipeline challenges in the industry - getting better treatments to market faster.

BASF, the world’s largest chemical company, has extensive ingredient formulation and material science expertise, as well as world-class excipient products and has been a leader in developing hot melt extrusion technology solutions. Catalent is the number one global partner in drug formulation and development as well as in finished oral dose manufacturing, with more than 75 years of experience in providing bioavailability solutions.